https://www.selleckchem.com/pr....oducts/liproxstatin-
Five-year OS estimates by TTC group were 0.82, 0.81, 0.80, and 0.74, respectively (p.001). BCSS demonstrated a similar trend (p.001). Chemotherapy delay was associated with worse OS (HR=1.33, 95%CI 1.25-1.4 and BCSS (HR=1.39, 95%CI 1.27-1.53). In subgroup analysis, delayed chemotherapy was associated with worse OS and BCSS among patients with hormone receptor-positive (HR=1.56, 95%CI 0.97-2.51), HER2-positive (HR=1.99, 95%CI 1.04-3.79), and triple-negative (HR=2.15, 95%CI 1.38-3.36) tumors. Chemotherapy delays are assoc
כמו
תגובה
לַחֲלוֹק
